Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.55 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 10/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 10/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 9/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 9/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23256877 | 0.89 | DYRK1A (0.57) | DYRK1AFSCN1CASP3SENP7SENP8 | |
| SCHEMBL21569130 | 0.87 | DYRK1A (0.56) | DYRK1AFSCN1CASP3SENP7SENP8 | |
| SCHEMBL21569189 | 0.87 | DYRK1A (0.56) | DYRK1AKDM4ENPC1NFKB1RAB9A | |
| SCHEMBL21568065 | 0.86 | DYRK1A (0.57) | DYRK1AFSCN1CASP3SENP7SENP8 | |
| SCHEMBL21568107 | 0.85 | DYRK1A (0.58) | DYRK1ALRRK2 | |
| SCHEMBL21568166 | 0.85 | DYRK1A (0.53) | DYRK1AFSCN1CASP3SENP7SENP8 | |
| SCHEMBL21569182 | 0.84 | DYRK1A (0.55) | DYRK1AFSCN1CASP3SENP7SENP8 | |
| SCHEMBL21568163 | 0.83 | CXCR2 (0.59) | DYRK1AFSCN1CASP3SENP7SENP8 | |
| SCHEMBL21568257 | 0.83 | KDM4E (0.61) | DYRK1AFSCN1CASP3SENP7SENP8 | |
| SCHEMBL23256634 | 0.83 | P2RY1 (0.42) | DYRK1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | DYRK1A 4664/4885FSCN1 2377/4885CASP3 87/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | DYRK1A 4618/4885FSCN1 2933/4885CASP3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.